List of Astepro Allergy drug patents
Astepro Allergy is owned by Bayer Hlthcare.
Astepro Allergy contains Azelastine Hydrochloride.
Astepro Allergy has a total of 3 drug patents out of which 0 drug patents have expired.
Astepro Allergy was authorised for market use on 17 June, 2021.
Astepro Allergy is available in spray, metered;nasal dosage forms.
Astepro Allergy can be used as otc use: allergy symptom reliever; temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose.
The generics of Astepro Allergy are possible to be released after 04 June, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518919 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(2 years from now) | |
| US9919050 | BAYER HLTHCARE | Compositions comprising azelastine |
Nov, 2025
(2 years from now) | |
| US8071073 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(5 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose
Dosage: SPRAY, METERED;NASAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic